
{
  "documentMetadata": {
    "title": "Anthrax, Systemic",
    "lastUpdated": "2025-04-25",
    "sourceFile": "Anthrax, Systemic.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Zoonotic disease:",
        "Animal reservoir: sheep, goats, cattle.",
        "Rarely, infection occurs secondary to use of illicit drugs.",
        "Inhalation or ingestion of Bacillus anthracis spores during exposure to contaminated animal wool, hair, hides or other animal products.",
        "Agent of bioterrorism.",
        "Vegetative form produces necrotizing toxins.",
        "Clinical syndrome varies with the route of inoculation:",
        "Systemic anthrax includes the following, with or without meningitis.",
        "Inhalational: chest x-ray shows mediastinal widening and/or pleural effusions.",
        "Oral.",
        "Gastrointestinal.",
        "See Cutaneous anthrax for treatment of this infection.",
        "Incubation period of 1-7 days, but up to 6 weeks or longer reported.",
        "Prodrome of fever, myalgias, and lethargy followed abrupt onset of respiratory failure and severe sepsis."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Bacillus anthracis"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "list",
      "items": [
        "Empiric therapy for systemic anthrax, without or without meningitis, based on 2023 CDC guidelines",
        "Treatment consists of an antibacterial regimen + antitoxin.",
        "Preferred antibacterial regimen is a three-drug combination regimen of two bactericidal drugs + a protein synthesis inhibitor or + RNA synthesis inhibitor (Rifampin), if possible.",
        "Second line antibacterial regimen: one bactericidal drug + a protein synthesis inhibitor.",
        "See 2023 CDC guidelines for two-drug and single drug alternatives to 3 drug regimen.",
        "Continue or switch antimicrobial drugs based on susceptibility test results.",
        "Can transition to an oral two-drug regimen (e.g., Ciprofloxacin + Doxycycline) to complete therapy based on patient improvement and clinical judgement.",
        "Non-pregnant adults age > 18 years",
        "Antibacterial regimen:",
        "Ciprofloxacin 400 mg IV q8h + Meropenem 2 gm q8h + (Minocycline 200 mg x 1 then 100 mg IV q12h or Doxycycline 200 mg IV x1 then 100 mg IV q12h)",
        "Duration of therapy 2 weeks or longer depending on clinical response",
        "Prolonged therapy no longer recommended for aerosol exposure for immunocompetent patients who will have developed natural immunity",
        "Immunocompromised patients with aerosol exposure should be transitioned to an oral post-exposure prophylaxis regimen to complete 60 days of therapy",
        "Antitoxin, administer one of the following:",
        "Raxibacumab (Abthrax)",
        "Premedicate with 25-50 mg of diphenhydramine IV or po",
        "40 mg/kg, one time dose",
        "Obiltoxaximab (Anthim)",
        "Premedicate with 25 mg of diphenhydramine IV or po",
        "16 mg/kg, one time dose",
        "Anthrax immune globulin intravenous",
        "420 units IV one time dose",
        "Pediatric regimen, age > 1 month to < 18 years (see Pediatrics 133:e1411, 2014):",
        "Antibacterial regimen:",
        "Ciprofloxacin 10 mg/kg (max dose 400 mg) IV q8h + Meropenem 40 mg/kg (max dose 2 gm) IV q8h + [Minocycline 4 mg/kg (max dose 200 mg) IV x1 then 2 mg/kg (max dose 100 mg) IV q12h or Doxycycline 4.4 mg/kg (max dose 200 mg) IV x1 then 2.2 mg/kg (max dose 100 mg) IV q12h]",
        "Duration of therapy 2 weeks or longer depending on clinical response",
        "Prolonged therapy no longer recommended for aerosol exposure for immunocompetent patients who will have developed natural immunity",
        "Immunocompromised patients with aerosol exposure should be transitioned to an oral post-exposure prophylaxis regimen to complete 60 days of therapy",
        "Antitoxin, administer one of the following:",
        "Raxibacumab (Abthrax)",
        "Premedicate with 25-50 mg of diphenhydramine IV or po",
        "≤10 kg: 80 mg/kg as a single dose IV",
        ">10 to 40 kg: 60 mg/kg as a single dose IV",
        ">40 kg: 40 mg/kg as a single dose IV",
        "Obiltoxaximab (Anthim)",
        "Premedicate with 25 mg of diphenhydramine IV or po",
        "≤15 kg: 32 mg/kg as a single dose IV",
        ">15 to 40 kg: 24 mg/kg as a single dose IV",
        ">40 kg: 16 mg/kg as a single dose IV",
        "Anthrax immune globulin intravenous",
        ">10 kg: 1 vial (approximately 60 units) IV",
        "10 to <18 kg: 2 vials (approximately 120 units) IV",
        "18 to <25 kg: 3 vials (approximately 180 units) IV",
        "25 to <35 kg: 4 vials (approximately 240 units) IV",
        "35 to <50 kg: 5 vials (approximately 300 units) IV",
        "50 to <60 kg: 6 vials (approximately 360 units) IV",
        "≥60 kg: 7 vials (approximately 420 units) IV",
        "Preterm and full-term newborns",
        "Antibacterial regimen:",
        "Meropenem + Ciprofloxacin + (Clindamycin or Doxycycline)",
        "Meropenem dosing: 32 to < 34 weeks gestational age, 0 to < 1 week, 13.3 mg/kg IV q8h; all others, 20 mg/kg IV q8h",
        "Ciprofloxacin dosing: 32 to < 34 weeks gestational age, 0 to < 1 week, 7.5 mg/kg IV q12h; all others, 12.5 mg/kg IV q12h",
        "Clindamycin dosing: 32 to < 37 weeks gestational age, 7 mg/kg IV/IM q8h; full-term, 9 mg/kg IV/IM q8h",
        "Doxycycline dosing: 32 to < 37 weeks gestational age, 5 mg/kg IV a12h: full-term, 5 mg/kg IV x1 then 2.5 mg/kg IV q12h",
        "Duration of therapy 2 weeks or or longer depending on clinical response then transition to an oral post-exposure prophylaxis regimen to complete a 60 day course of therapy if an aerosol exposure might have occurred as preterm and full-term newborns are considered immunocompromised; post-exposure prophylaxis not needed for non-aerosol exposures.",
        "Antitoxin, administer one of the following:",
        "Raxibacumab (Abthrax)",
        "Premedicate with 25-50 mg of diphenhydramine IV or po",
        "55 mg/kg as a single dose IV",
        "Obiltoxaximab (Anthim)",
        "Premedicate with 25 mg of diphenhydramine IV or po",
        "16 mg/kg as a single dose IV",
        "Anthrax immune globulin intravenous",
        "60 units IV",
        "Pregnant and lactating adults",
        "Antibacterial regimen:",
        "Ciprofloxacin 400 mg IV q8h + Meropenem 2 gm q8h + Doxycycline 200 mg x1 then 100 mg IV q12h",
        "Duration of therapy 2 weeks or longer depending on clinical response",
        "Prolonged therapy no longer recommended for aerosol exposure for immunocompetent patients who will have developed natural immunity.",
        "Immunocompromised patients, pre-term and full-term newborns with aerosol exposure should be transitioned to an oral post-exposure prophylaxis regimen to complete 60 days of therapy",
        "Antitoxin: same as for non-pregnant adults"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "See 2023 CDC guidance for alternative two-drug combination or single drug regimens and specific recommendations for dosing",
        "Alternative bactericidal drugs",
        "Alternatives to Ciprofloxacin: Levofloxacin or Moxifloxacin",
        "Alternatives to Meropenem: Imipenem (avoid in meningitis) or Vancomycin",
        "Piperacillin-tazobactam or Ampicillin-sulbactam are possible alternatives but activity against penicillin-resistant strains not established",
        "For penicillin-susceptible strains only: Penicillin G or Ampicillin",
        "Oral alternatives for penicillin-susceptible strains: Amoxicillin or Penicillin VK",
        "Alternative protein-synthesis inhibitors or RNA synthesis inhibitors",
        "Alternatives to Doxycycline or Minocycline: Linezolid, Rifampin, Clindamcyin, Omadacycline, Eravacycline, or Chloramphenicol"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "To report a possible bioterrorism event to CDC: (+1) 770-488-7100.",
        "Recent References:",
        "2023 CDC Guidelines",
        "Clinical features (Clin Infect Dis 2022, 75: S341)",
        "Treatment outcomes (Clin Infect Dis 2022, 75: S392)",
        "Antitoxin (Clin Infect Dis 2022, 75: S432)"
      ]
    }
  ]
}
